<DOC>
	<DOCNO>NCT00352131</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , maytansinoid DM4-conjugated humanize monoclonal antibody huC242 , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . PURPOSE : This phase I trial study side effect best dose maytansinoid DM4-conjugated humanize monoclonal antibody huC242 treat patient solid tumor remove surgery spread part body .</brief_summary>
	<brief_title>Maytansinoid DM4-Conjugated Humanized Monoclonal Antibody huC242 Treating Patients With Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine dose-limiting toxicity maximum tolerate dose maytansinoid DM4-conjugated humanize monoclonal antibody huC242 patient inoperable metastatic colorectal cancer , pancreatic cancer , solid tumor . Secondary - Determine qualitative quantitative toxicity drug patient . - Characterize pharmacokinetics drug patient . - Describe antitumor activity drug patient . OUTLINE : This open-label , nonrandomized , dose-escalation study . Patients receive maytansinoid DM4-conjugated humanize monoclonal antibody huC242 IV 4-5 hour day 1 . Treatment repeat every 3 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos maytansinoid DM4-conjugated humanize monoclonal antibody huC242 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Up 15 patient treated MTD . Patients undergo blood collection baseline periodically study pharmacokinetic study . After completion study treatment , patient follow 30 day . PROJECTED ACCRUAL : A total 40 patient accrue study .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm solid tumor Inoperable metastatic disease Failed standard therapy Confirmed cancer antigen ( CanAg ) expression Patients must noncolorectal cancer pancreatic cancer Tumor must homogeneous pattern ( i.e. , stain present &gt; 75 % tumor cell CanAg ) 2+ 3+ intensity immunohistochemistry * No known leptomeningeal disease progressive brain disease PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy ≥ 12 week Absolute neutrophil count ≥ 1,500/mm³ Hemoglobin ≥ 9 g/dL ( transfusion allow ) Platelet count ≥ 100,000/mm³ aPTT INR ≤ 1.5 time upper limit normal ( ULN ) Creatinine ≤ 1.5 mg/dL Creatinine clearance ≥ 60 mL/min Bilirubin ≤ 1.5 mg/dL AST ALT &lt; 2.5 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 30 day completion study treatment No hypersensitivity agent class study drug , humanize nonhumanized antibody , immunoconjugates No active , uncontrolled infection No hepatitis B surface antigen hepatitis C antibody positivity No history alcoholic liver disease No serious medical psychiatric disorder would preclude compliance study requirement No peripheral neuropathy &gt; grade 1 No malignancy within past 2 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , stage A lowgrade prostate cancer No severe concurrent disease condition , opinion investigator , would preclude study participation PRIOR CONCURRENT THERAPY : Recovered prior therapy At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin C ) At least 4 week since prior radiotherapy , immunotherapy , hormone therapy cancer At least 4 week since prior major surgery No concurrent chemotherapy , immunotherapy , radiotherapy , investigational therapy Palliative radiotherapy relate bone metastasis allow No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
</DOC>